This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions
The last NephJC of the year brought us a cool discussion on if cooling dialysate could help mitigate the effects of intradialytic hypotension. Get caught up with the chat in the latest edition of #TenTweetNephJC.
Episode 042: Minimal change disease has classically been described as having negative immunofluorescence and to not be antibody mediated. But here comes Dr Weans with a fresh study smashing this orthodoxy. She proposes anti-nephrin antibodies as the etiologic agent driving minimal change disease.
Episode 044: The University of Alabama with Revicor have made a better pig. Better for transplanting. And they transplanted a pair of these into a brain dead patient. The filtrate discuss the case report with transplant surgeon, Josh Mezrich.
Episode 045: Switching table salt to a blend of sodium and potassium chloride reduces stroke and improves total mortality. What’s not to like?
Episode 046: The Guideline Draft is back! This time the 2022 ISPD Peritonitis Guidelines are on the clock! The Filtrate are joined by PD junky Jade Teakell and guideline author, Jeff Perl.
Episode 047: This is a guideline shredding study. This landmark study of blood pressure in pregnancy is going to change how we approach hypertension in pregnancy.
Episode 048: TESTING is the latest IgA nephropathy trial and it is the comeback kid of nephrology trials. From a trial that was halted because of excess adverse events to a safe and effective therapy with just a few tweeks. Amazing turn around. Join the Filtrate as we put TESTING to the test with study author Sean Barbour.
Episode 049: SODIUM-HF is the largest and longest RCT done looking at sodium restriction heart failure. The top line results show no effect but the more you look at the study the more problematic it is. The Filtrate take it to task.
Freely Filtered 050: CLASSIC Trial. The Filtrate look at the latest contribution to Fluid Wars, this one looking at late resuscitation.
The Filtrate looks at a trial that tries to dissect the bumps in creatinine we regularly see with Pip/Tazo. Is it AKI or pseudonephrotoxicity?
ADVOR turns the practice of sequential nephron blockade on its head by blocking the proximal tubule before the loop of Henle. Does it work? Join The Filtrate as we dissect the latest diuretic RCT.
Freely Filtered 054: EMPA-Kidney. EMPA-Kidney is the last of the big three to report their Kidney Endpoints SGLT2i trial (CREDENCE for Cana, DAPA-CKD for Dapa, and now EMPA-Kidney for Empa) and it answers some questions that had previously been unanswered. Join the Filtrate as they tear it apart.
This week we discussed aprocitentan, another endothelin receptor antagonist, this time being explored in the resistant hypertension arena - you know the #TenTweetNephJC drill, if you want a rapid catch up then here’s your place!
Is Aprocitentan effective in lowering BP in resistant hypertension? PRECISION trial answers it with a meticulous design. Checkout the VA by NSMC intern Sandhya Suresh which captures many elements of that meticulous design.
Friend of NephJC, Daniel Schwartz does a nice tweetorial on EMPA-Kidney
If you missed the latest NephJC discussion, at least read the highlights here.
You gotta know when to hold’em and know when to fold’em. Review the #TenTweetNephJC for the STOP ACEi Trial, and always hold onto your ACEi.
